# A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

> **NCT02320435** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 154 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Other Combination Anti-Cancer Therapies

## Key facts

- **NCT ID:** NCT02320435
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320435, "A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02320435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*